Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Churchill Capital Corp XI - Class A Ordinary Shares (NQ:CCXI)

13.86 -0.14 (-1.00%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 31, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Churchill Capital Corp XI - Class A Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
24 Stocks Moving in Friday's Pre-Market Session ↗
Gainers Vinco Ventures, Inc. (NASDAQ: BBIG) shares rose 35% to $3.47 in pre-market trading. Vinco Ventures set record date as May 18, 2022 For dividend of shares related to Cryptyde deal. The dividend... 
Via Benzinga
News headline image
ChemoCentryx: Q1 Earnings Insights ↗
ChemoCentryx (NASDAQ:CCXI) reported its Q1 earnings results on Thursday, May 5, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings ChemoCentryx missed estimated... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
Gainers 
Via Benzinga
News headline image
ChemoCentryx's Earnings: A Preview ↗
ChemoCentryx (NASDAQ:CCXI) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that ChemoCentryx... 
Via Benzinga
News headline image
ChemoCentryx Posts Favorable PK, PD Results Of Oral PD-L1 Inhibitor In Cancer ↗
 
Via Benzinga
News headline image
Why ChemoCentryx Shares Are Falling ↗
ChemoCentryx Inc (NASDAQ:CCXI) shares are trading lower by... 
Via Benzinga
News headline image
Recap: ChemoCentryx Q4 Earnings ↗
ChemoCentryx (NASDAQ:CCXI) reported its Q4 earnings results on Tuesday, March 1, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings... 
Via Benzinga
News headline image
NASDAQ: CCXI Investor Notice: Update in Lawsuit Against ChemoCentryx, Inc. Announced ↗
San Diego, CA -- (SBWIRE) -- 04/26/2022 -- An update was announced in the lawsuit that is pending for certain investors in in shares of ChemoCentryx, Inc. (NASDAQ: CCXI) against ChemoCentryx, Inc.over... 
Via SBWire
News headline image
Bonds Are Screaming “Recession.” That’s Great News For One Top Sector. ↗
The 10-2 year treasury yield spread is close to zero. Here's what you should do about this warning sign of a coming recession. 
Via InvestorPlace
News headline image
CHEMOCENTRYX INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of ChemoCentryx, Inc. - CCXI
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
News headline image
Earnings Scheduled For March 1, 2022 ↗
Companies Reporting Before The Bell • Precigen (NASDAQ:PGEN) is expected to report earnings for its fourth quarter. • TG Therapeutics (NASDAQ:TGTX) is estimated... 
Via Benzinga
News headline image
Earnings Preview: ChemoCentryx ↗
ChemoCentryx (NASDAQ:CCXI) is set to give its latest quarterly earnings report on Tuesday, 2022-03-01. Here's what investors need to know before the announcement. Analysts... 
Via Benzinga
News headline image
Why ChemoCentryx Shares Are Rising ↗
ChemoCentryx Inc (NASDAQ:CCXI) shares are trading higher a... 
Via Benzinga
News headline image
ChemoCentryx's Return On Capital Employed Insights ↗
ChemoCentryx (NASDAQ:CCXI) brought in sales totaling $2.31 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 81.68%, resulting in a loss of... 
Via Benzinga
News headline image
68 Biggest Movers From Yesterday ↗
Gainers ECMOHO Limited (NASDAQ: MOHO) climbed 56.7% to close at $0.3650 on Wednesday after jumping 10% on Tuesday. Imperial Petroleum Inc. (NASDAQ: IMPP) shares jumped 39.2% to... 
Via Benzinga
News headline image
See Why Is Stifel Analyst 'Perplexed' After ChemoCentryx Q4 Earnings ↗
Stifel has reiterated a Buy rating and $85 price target on ChemoCentryx Inc (NASDAQ: CCXI) following the Q4 results. Analyst Dae Gon Ha says he is "... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
Gainers Trevi Therapeutics (NASDAQ:TRVI) shares rose 46.6% to $1.28 during Wednesday's regular session. As of 12:30 EST, Trevi Therapeutics's stock is trading at a... 
Via Benzinga
News headline image
41 Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers ECMOHO Limited (NASDAQ: MOHO) jumped 67% to $0.3890 after jumping 10% on Tuesday. Nordstrom, Inc. (NYSE: JWN) shares jumped 38.7% to $27.11 after the company reported... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
Gainers IsoPlexis (NASDAQ:ISO) shares moved upwards by 22.8% to $5.5 during Wednesday's pre-market session. The company's market cap stands at $214.2 million. The... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Karyopharm Flags Delay In Selinexor Label Expansion, Finch, Celyad Hit With Clinical Holds, Adagene Strikes R&D Collaboration With Sanofi ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Karyopharm Says FDA Mandates Additional Study For Expanding Selinexor Label... 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗
Rise and shine, trader! It's time to start off another day of trading with the biggest pre-market stock movers for Wednesday! 
Via InvestorPlace
News headline image
28 Stocks Moving in Wednesday's Pre-Market Session ↗
Gainers Guardion Health Sciences, Inc. (NASDAQ: GHSI) rose 46.4% to $0.4098 in pre-market trading after jumping around 48% on Tuesday. Guardion Health Sciences recently reported... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Legend Biotech, CTI Biopharma Receive FDA Approvals, AbbVie Announces Delay In Skyrizi Review, Editas Gains On CRISPR Patent Resolution ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Editas Gains On Resolution Of CRISPR Gene Editing Patent Case Editas Medicine... 
Via Benzinga
News headline image
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight ↗
Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first... 
Via Benzinga
News headline image
Is Now The Time To Buy Stock In ChemoCentryx, Ideanomics Or Snowflake? ↗
Analysts and brokerage firms often use ratings when they issue stock recommendations to stock traders. Analysts arrive at stock ratings b... 
Via Benzinga
News headline image
NASDAQ:CCXI Long Term Investor Alert: Investigation of Potential Wrongdoing at ChemoCentryx, Inc. ↗
San Diego, CA -- (SBWIRE) -- 02/24/2022 -- An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of ChemoCentryx, Inc. 
Via SBWire
News headline image
NASDAQ:CCXI Investor Notice: Investigation over Possible Securities Laws Violations by ChemoCentryx, Inc. ↗
San Diego, CA -- (SBWIRE) -- 02/22/2022 -- ChemoCentryx, Inc. is under investigation over potential securities laws violations in connection with certain financial statements. 
Via SBWire
News headline image
SHAREHOLDER ALERT: Robbins LLP Investigates ChemoCentryx, Inc. (CCXI) on Behalf of Shareholders
From Robbins LLP
Via Business Wire
News headline image
ChemoCentryx's Avacopan Scores European Approval For ANCA-Associated Vasculitis ↗
The European Union has approved ChemoCentryx Inc's (NASDAQ: CCXI) Tavneos (avacopan) for ANCA-associated vasculitis. The approval follows the FDA approval of... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.